

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549  
 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076  
 Estimated average burden hours per response: 4.00

1. Issuer's Identity

<b>CIK (Filer ID Number)</b> <a href="#">0001169245</a>	<b>Previous Names</b> None	<b>Entity Type</b>
<b>Name of Issuer</b> PhaseBio Pharmaceuticals Inc	Phase Biosciences Inc DT BIOSCIENCES INC	<input checked="" type="checkbox"/> Corporation <input type="checkbox"/> Limited Partnership <input type="checkbox"/> Limited Liability Company <input type="checkbox"/> General Partnership <input type="checkbox"/> Business Trust <input type="checkbox"/> Other (Specify)
<b>Jurisdiction of Incorporation/Organization</b> DELAWARE		
<b>Year of Incorporation/Organization</b> <input checked="" type="checkbox"/> Over Five Years Ago <input type="checkbox"/> Within Last Five Years (Specify Year) <input type="checkbox"/> Yet to Be Formed		

2. Principal Place of Business and Contact Information

<b>Name of Issuer</b> PhaseBio Pharmaceuticals Inc			
<b>Street Address 1</b> 1 Great Valley Parkway		<b>Street Address 2</b> Suite 30	
<b>City</b> Malvern	<b>State/Province/Country</b> PENNSYLVANIA	<b>ZIP/PostalCode</b> 19355	<b>Phone Number of Issuer</b> 610-608-8563

3. Related Persons

<b>Last Name</b> Prior	<b>First Name</b> Christopher	<b>Middle Name</b>
<b>Street Address 1</b> 1 Great Valley Parkway	<b>Street Address 2</b> Suite 30	
<b>City</b> Malvern	<b>State/Province/Country</b> PENNSYLVANIA	<b>ZIP/PostalCode</b> 19355
<b>Relationship:</b> <input checked="" type="checkbox"/> Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

<b>Last Name</b> Sussman	<b>First Name</b> Joel	<b>Middle Name</b>
<b>Street Address 1</b> 1 Great Valley Parkway	<b>Street Address 2</b> Suite 30	
<b>City</b> Malvern	<b>State/Province/Country</b> PENNSYLVANIA	<b>ZIP/PostalCode</b> 19355
<b>Relationship:</b> <input checked="" type="checkbox"/> Executive Officer <input type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Chilkoti	Ashutosh	
Street Address 1	Street Address 2	
1001 Gloria Avenue		
City	State/Province/Country	ZIP/PostalCode
Durham	NORTH CAROLINA	27701
<b>Relationship:</b>	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Thorp	Clay	
Street Address 1	Street Address 2	
208 S. Mangum Street	Suite 350	
City	State/Province/Country	ZIP/PostalCode
Durham	NORTH CAROLINA	27701
<b>Relationship:</b>	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Xavier	Asish	K
Street Address 1	Street Address 2	
410 George Street		
City	State/Province/Country	ZIP/PostalCode
New Brunswick	NEW JERSEY	08901
<b>Relationship:</b>	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Fish	Guy	
Street Address 1	Street Address 2	
222 Berkeley Street	20th Floor	
City	State/Province/Country	ZIP/PostalCode
Boston	MASSACHUSETTS	02116
<b>Relationship:</b>	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Ingram	Robert	
Street Address 1	Street Address 2	
280 S. Mangum Street	Suite 350	
City	State/Province/Country	ZIP/PostalCode
Durham	NORTH CAROLINA	27701
<b>Relationship:</b>	Executive Officer X Director	Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Rosen	Craig	
Street Address 1	Street Address 2	
370 Eagle Hill Road		
City	State/Province/Country	ZIP/PostalCode
Pasadena	MARYLAND	21122

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Klein	Justin	
Street Address 1	Street Address 2	
5425 Wisconsin Avenue	Suite 800	
City	State/Province/Country	ZIP/PostalCode
Chevy Chase	MARYLAND	20815

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

---

Last Name	First Name	Middle Name
Barrett	James	
Street Address 1	Street Address 2	
1119 St. Paul Street		
City	State/Province/Country	ZIP/PostalCode
Baltimore	MARYLAND	21202

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

#### 4. Industry Group

Agriculture	Health Care	Retailing
Banking & Financial Services	X Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Insurance	Hospitals & Physicians	Computers
Investing	Pharmaceuticals	Telecommunications
Investment Banking	Other Health Care	Other Technology
Pooled Investment Fund	Manufacturing	Travel
Is the issuer registered as an investment company under the Investment Company Act of 1940?	Real Estate	Airlines & Airports
Yes No	Commercial	Lodging & Conventions
Other Banking & Financial Services	Construction	Tourism & Travel Services
Business Services	REITS & Finance	Other Travel
Energy	Residential	Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		

#### 5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000

\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000
Over \$100,000,000	Over \$100,000,000
X Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505
Rule 504 (b)(1)(i)	X Rule 506
Rule 504 (b)(1)(ii)	Securities Act Section 4(5)
Rule 504 (b)(1)(iii)	Investment Company Act Section 3(c)
	Section 3(c)(1)                      Section 3(c)(9)
	Section 3(c)(2)                      Section 3(c)(10)
	Section 3(c)(3)                      Section 3(c)(11)
	Section 3(c)(4)                      Section 3(c)(12)
	Section 3(c)(5)                      Section 3(c)(13)
	Section 3(c)(6)                      Section 3(c)(14)
	Section 3(c)(7)

7. Type of Filing

New Notice    Date of First Sale 2009-12-22    First Sale Yet to Occur  
 Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?    Yes  No

9. Type(s) of Securities Offered (select all that apply)

<input checked="" type="checkbox"/> Equity	Pooled Investment Fund Interests
<input type="checkbox"/> Debt	Tenant-in-Common Securities
<input type="checkbox"/> Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
<input type="checkbox"/> Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?    Yes  No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient	Recipient CRD Number <input checked="" type="checkbox"/> None
(Associated) Broker or Dealer <input checked="" type="checkbox"/> None	(Associated) Broker or Dealer CRD Number <input checked="" type="checkbox"/> None

**Street Address 1**

**Street Address 2**

City	State/Province/Country	ZIP/Postal Code
------	------------------------	-----------------

State(s) of Solicitation (select all that apply)  
 Check "All States" or check individual States    All States    Foreign/non-US

### 13. Offering and Sales Amounts

Total Offering Amount      \$25,300,001 USD or    Indefinite

Total Amount Sold          \$25,300,001 USD

Total Remaining to be Sold      \$0 USD or    Indefinite

Clarification of Response (if Necessary):

### 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.  

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 12

### 15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions              \$0 USD    Estimate

Finders' Fees                    \$0 USD    Estimate

Clarification of Response (if Necessary):

### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD    Estimate

Clarification of Response (if Necessary):

Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.

### Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

<b>Issuer</b>	<b>Signature</b>	<b>Name of Signer</b>	<b>Title</b>	<b>Date</b>
PhaseBio Pharmaceuticals Inc	Joel F. Sussman	Joel F. Sussman	Chief Financial Officer	2010-12-02

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

---